J Neuropathol Exp Neurol 2021 Apr 16. Epub 2021 Apr 16.
From the Department of Pathology and Laboratory Medicine (JMW, KFB, TER); Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases (JMW, KFB, SS, TER), University of Texas Health Science Center, San Antonio, Texas, USA; Department of Pathology, State University of New York, Upstate Medical University, Syracuse, New York (YF, TER); Department of Pathology, University of Michigan, Ann Arbor, Michigan (YF), USA; Department of Pathology (KF, MAI, JFC); Department of Neuroscience (KF, MAI, JFC); Ronald M. Loeb Center for Alzheimer's Disease (KF, MAI, JFC), Icahn School of Medicine at Mount Sinai, New York, New York, USA; School of Medicine, University of Michigan, Ann Arbor, Michigan (MAI); Department of Neuroscience, Mayo Clinic, Jacksonville, Florida (KFB), USA; Department of Neurology, University of Texas Health Science Center, San Antonio, Texas (SS); The Framingham Heart Study, Framingham, Massachusetts (SS); and Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas (CLW), USA.
Primary age-related tauopathy (PART) is a neurodegenerative entity defined as neurofibrillary degeneration generally restricted to the medial temporal region (Braak stage I-IV) with complete or near absence of diffuse and neuritic plaques. Symptoms range in severity but are generally milder and later in onset than in Alzheimer disease (AD). Recently, an early predilection for neurofibrillary degeneration in the hippocampal CA2 subregion has been demonstrated in PART, whereas AD neuropathologic change (ADNC) typically displays relative sparing of CA2 until later stages. Read More